Dublin, May 15, 2025 (GLOBE NEWSWIRE) -- The "Actemra (Tocilizumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets.com's offering.
This Actemra (Tocilizumab) market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Actemra (Tocilizumab) is a prescription biologic medication classified as an interleukin-6 (IL-6) receptor antagonist, used to treat various autoimmune and inflammatory conditions. It works by inhibiting IL-6, a cytokine involved in inflammation, which helps reduce symptoms and prevent disease progression in conditions such as rheumatoid arthritis, giant cell arteritis, and cytokine release syndrome.
The primary product types of actemra (tocilizumab) are categorized by purity levels less than 98%, between 98% and 99%, and more than 99%. The less than 98% purity includes tocilizumab products that may have more impurities or residual components, potentially affecting efficacy and safety. The dosages available are injection, solution, and concentrate, with routes of administration including oral, parenteral, and others. Distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies. Actemra is used in various applications such as cytokine release syndrome (CRS), systemic juvenile idiopathic arthritis (SJIA), giant cell arteritis (GCA), and rheumatoid arthritis (RA).
Major players operating in the actemra (tocilizumab) market are Roche Holding AG; Fresenius Kabi. North America was the largest region in the actemra (Tocilizumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in actemra (tocilizumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the actemra (tocilizumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Market growth during the historic period can be attributed to the rising prevalence of autoimmune diseases, the increasing adoption of biologic therapies, growing awareness about chronic inflammatory conditions, strong regulatory approvals in key markets, and expanding healthcare infrastructure in developed regions.
Market growth during the forecast period is driven by the expansion of therapeutic applications, including COVID-19 cytokine release syndrome, a growing demand for personalized medicine, the development and adoption of biosimilars, rising healthcare expenditure in emerging markets, and increased awareness of biologic therapies in developing regions. Major trends in the forecast period include the increasing adoption of subcutaneous formulations, a focus on biosimilar development for cost reduction, advancements in biotechnology for enhanced drug delivery systems, ongoing clinical trials for new therapeutic indications, and strategic partnerships and investments by pharmaceutical companies.
The rising prevalence of rheumatoid arthritis is expected to propel the growth of the actemra (tocilizumab) market. Rheumatoid arthritis is a chronic autoimmune condition that leads to joint inflammation, damage, and reduced quality of life, affecting millions globally. Factors such as smoking, obesity, environmental exposures, and hormonal influences contribute to the rise in cases. Actemra (tocilizumab) works by inhibiting the interleukin-6 (IL-6) receptor, reducing inflammation, and preventing joint damage in patients who have not responded to other treatments.
A key trend in the actemra (tocilizumab) market is the development of biosimilars, which provide a more affordable alternative to the original drug. Biosimilars are approved to treat autoimmune diseases, offering similar efficacy to the originator drug, Actemra. For example, in November 2023, Fresenius Kabi launched Tyenne, the first tocilizumab biosimilar referencing RoActemra (tocilizumab) in the European Union. Tyenne is approved for treating multiple inflammatory and immune diseases, including rheumatoid arthritis, giant cell arteritis, and cytokine release syndrome (CRS). This development is expected to increase market competition and provide more treatment options at lower costs.
In September 2024, Bio-Thera Solutions Ltd., a China-based biopharmaceutical company, partnered with Biogen Inc. to publish Phase 3 clinical trial data for TOFIDENCE (BAT1806/BIIB800), a biosimilar to Actemra. TOFIDENCE aims to expand treatment access for autoimmune conditions. Biogen Inc. is a US-based biotechnology company specializing in therapies for neurological and autoimmune diseases. This partnership is set to enhance the growth of the Actemra market by broadening treatment options and improving access to affordable therapies.
Key Topics Covered:
1. Executive Summary
2. Actemra (Tocilizumab) Market Characteristics
3. Actemra (Tocilizumab) Market Biologic Drug Characteristics
3.1. Molecule Type
3.2. Route of Administration (ROA)
3.3. Mechanism of Action (MOA)
3.4. Safety and Efficacy
4. Actemra (Tocilizumab) Market Trends and Strategies
5. Actemra (Tocilizumab) Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market
6. Global Actemra (Tocilizumab) Growth Analysis and Strategic Analysis Framework
6.1. Global Actemra (Tocilizumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
6.2. Analysis of End Use Industries
6.3. Global Actemra (Tocilizumab) Market Growth Rate Analysis
6.4. Global Actemra (Tocilizumab) Historic Market Size and Growth, 2019-2024, Value ($ Billion)
6.5. Global Actemra (Tocilizumab) Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)
6.6. Global Actemra (Tocilizumab) Total Addressable Market (TAM)
7. Global Actemra (Tocilizumab) Market Pricing Analysis & Forecasts
8. Actemra (Tocilizumab) Market Segmentation
8.1. Global Actemra (Tocilizumab) Market, Segmentation by Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Min Purity Less Than 98%
- Min Purity 98%-99%
- Min Purity More Than 99%
8.2. Global Actemra (Tocilizumab) Market, Segmentation by Dosage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Injection
- Solution
- Concentrate
8.3. Global Actemra (Tocilizumab) Market, Segmentation by Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Parenteral
- Other Routes of Administration
8.4. Global Actemra (Tocilizumab) Market, Segmentation by Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
8.5. Global Actemra (Tocilizumab) Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Cytokine Release Syndrome (CRS)
- Systemic Juvenile Idiopathic Arthritis (sJIA)
- Giant Cell Arteritis (GCA)
- Rheumatoid Arthritis (RA)
9. Global Actemra (Tocilizumab) Market Epidemiology of Clinical Indications
9.1. Drug Side Effects
9.2. Incidence and Prevalence of Clinical Indications
10. Actemra (Tocilizumab) Market Regional and Country Analysis
10.1. Global Actemra (Tocilizumab) Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. Global Actemra (Tocilizumab) Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
For more information about this report visit https://www.researchandmarkets.com/r/y30950
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
